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Global cancer centres operate across different sizes, scales, and ecosystems. Understanding the essential aspects of 
the creation, organisation, accreditation, and activities within these settings is crucial for developing an affordable, 
equitable, and quality cancer care, research, and education system. Robust guidelines are scarce for cancer units, 
cancer centres, and comprehensive cancer centres in low-income and middle-income countries. However, some 
robust examples of the delivery of complex cancer care in centres in emerging economies are available. Although it is 
impossible to create an optimal system to fit the unique needs of all countries for the delivery of cancer care, we 
summarise what has been published about the development and management of cancer centres in low-income and 
middle-income countries so far and highlight the need for clinical and political leadership.
Introduction
The progress of cancer management has been marked by 
rapid growth of the research endeavour and the increased 
need to deliver complex care across different health 
ecosystems, topographies, and countries. In the past 
decade, key drivers for improved global cancer research 
and the delivery of affordable a nd equitable care have 
been examined.1 This effort t o i dentify i ssues, barriers, 
and solutions that are suitable for global cancer control 
has mostly focused on specific areas including women’s 
cancers,2 surgery, radiotherapy,3,4 continents and countries 
(eg, Africa,5 India,6 and Latin America7), and conceptual 
frameworks (eg, universal health coverage, the so-called 
grand convergences in health,8 and the 25-by-25 goals 
[reduction of premature mortality by 25% by 2025]9). 
Additionally, capacity and capability building (eg, 
Zambia’s progress against cervical cancer10), innovation 
and tech nology,11 resource stratification a round m odels 
of care, and workforce planning have been popular 
themes for discussion and analysis. However, the 
organisational and structural framing—cancer units, 
cancer centres, and compre hensive cancer centres 
(panel 1)—have been largely absent from the discussion. 
In this Review, we explore factors that influence t he 
development of a cancer centre, key experiences, lessons 
learnt from the development of these centres in specific 
countries and regions, and challenges in delivering 
cancer care in diverse situations.
In any policy study, the normative framework for 
analysis should incorporate both critical and positive 
components; however, there is a dearth of empirical 
work on the former. No cancer centre model system has 
been subjected to any type of in-depth qualitative or 
quantitative analysis; even peer reviews of cancer 
centres by supranational bodies (such as WHO and 
International Atomic Energy Agency), and national 
systems, do not have transparent methodologies and are 
unpublished and unverifiable in terms on their effect on 
cancer care. Even when analysis of cancer centres is 
reasonably transparent, the effect on outcomes, or 
indeed any metric of improved cancer control, is absent. 
Therefore, any critique of individual cancer centres or 
models for cancer centre development remain highly 
subjective and so here we focus on a positivist analytical 
framework.
Global cancer centres operate across a wide range 
of sizes, scales, and ecosystems. Understanding 
the essential aspects of the creation, organisation, 
accreditation, and activities within these settings is 
crucial for developing an affordable, equitable, and 
quality cancer care, research, and education system. 
The growing burden of cancer in low-income and 
middle-income countries (LMICs), in particular, has led 
to an opportunistic increase in the number of cancer 
centres with little or no regulation or transparent 
national accountability. Any hospital that treats a 
Panel 1: Definition of cancer centres
The term cancer centre broadly covers three types of establishment treating patients with 
cancer, as defined in high-income settings:
• Cancer units are usually dedicated cancer wards within the general hospital setting, 
including nursing homes and hospices, particularly in low-income and middle-income 
countries (LMICs)
• Cancer centres are dedicated multispecialty centres that can be stand alone or part 
of a general hospital complex, including site-specific cancer centres (eg, 
haemato-oncology, breast, radiotherapy, hepato-pancreato-biliary, and palliative) 
often referred to as secondary or district cancer centres (as seen in most National 
Health Service hospitals in the UK)
• Comprehensive cancer centres are the highest tier and cover multidisciplinary centres 
that might be stand alone or part of general hospital complexes. These centres deliver 
not only the full range of cancer care, but also prevention, research, training, and 
education locoregionally or nationally and are often subject to national and 
international accreditation processes (eg, National Cancer Institute accreditation in 
the USA or Organisation of European Cancer Institute accreditation across Europe). 
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patient with cancer can call itself a comprehensive 
cancer centre, irrespective of the facilities, qualifi-
cations, or expertise that are available to the centre. In 
this health policy analysis, we examine cancer from a 
structural and organisational perspective, focusing on 
the profession alisation of cancer centres as part of the 
emergence of global attention on all aspects of health-
system strenghtening.12 Figure 1 shows the factors that 
can influence the development of a cancer centre.
Cancer centre development
The organisation of cancer care into specific centres 
happened organically through early developments in 
cancer therapeutics and the move from cancer as a 
terminal condition to one that could be treated with 
curative intent.13 Models for cancer care were first 
developed in the late 1800s with the creation of specific 
wards dedicated to cancer in general hospitals.14 The 
increase of research into cancer gave rise to early 
prototype cancer centres such as the University of 
Buffalo Pathological Laboratory that was opened in 1898, 
which became the National Cancer Institute-designated 
Roswell Park Cancer Institute in 1992, and Memorial 
Sloan Kettering Cancer Centre, which opened in 1884 
as a New York cancer hospital on Manhattan’s Upper 
West Side. In Europe, the Royal Marsden in the UK, 
the Institut Gustave Roussey cancer centre in France, 
Radiumhemmet in Solina, Sweden, and the Netherlands 
Cancer Institute in Amsterdam, were all opened be-
tween the 1920s and the 1950s.
Early development of the cancer centre model also 
happened in LMICs. In India, the creation of the CSI 
Medical Mission Hospital, Neyyoor, south India, in 1831, 
the Tata Memorial Centre, Mumbai, in 1941, and the 
Cancer Institute (Women’s Indian Association), Chennai, 
in 1950 ushered in a new era of cancer centres across 
India. In Latin America, some cancer centres rose to early 
prominence, including the Dr Alrnaldo Cancer Institute, 
which was opened in 1920, the Radium Institute, Belo 
Horizonte, in Brazil, which was opened in 1922, and the 
Cancer Centre of the Federal District, which led to the 
creation of the Brazilian cancer centre network (Instituto 
Nacional de Cáncer) in 1937. Other cancer centres that 
opened in this period included the National Cancer 
Institute, Bogotá, Colombia (1934), National Cancer 
Institute, Lima, Peru (1939), and Mexico City, Mexico 
(1946). China established their first cancer centre as the 
Shanghai Cancer Institute (1931), and the Cancer Institute 
of the Chinese Academy of Medical Sciences, Beijing 
(1958). In the Middle East, Iran and Egypt led the way 
with the Cancer Institute, Tehran, Iran (1949) and the 
National Cancer Institute, Cairo, Egypt (1950).
The formal organisation and accreditation of cancer 
centres started in the USA with the 1971 National 
Cancer Act, which led to the creation of the National 
Cancer Institute and other comprehensive cancer 
centres for the country.15 In other high-income settings, 
cancer centre development has taken a bottom-up 
approach. The establishment of Institut National du 
Cancer in France in the mid-2000s led to the 
formalisation of cancer centres within national legis-
lation that mandated research and care, as well as 
budget allocation. Cancer centres in other European 
Union countries have evolved in a similar way but with 
different legislative framing and funding. In the past 
5 years, the Organisation of European Cancer Institutes, 
originally founded in 1979, has begun a formal system 
of cancer centre accreditation  for cancer centres in 
Europe.16 Additionally, international accreditation 
schemes have been developed, some of which are 
generic (eg, Joint Care Commission), and some of 
which are specific to cancer (eg, European Society of 
Medical Oncology designated centres for integrative 
oncology and palliative care). Various emerging powers 
have also begun formal processes and networks for the 
national accreditation of cancer centres—eg, the 
National Cancer Grid of India.17
Cancer centre development in high-income 
settings
Service and research
The development of cancer centres in high-income 
settings over the past 50 years has been driven by three 
key factors: first, the need to provide increased volumes of 
care with increased quality (eg, in onco-surgery18) by use 
of complex models of care; second, the need to deliver 
affordable, multidisciplinary care with the realisation that 
major cancer centres provide economies of scale; and 
third, the rapid emergence of translational cancer 
research requiring close interactions between laboratories 
and the clinic.19 Central to the delivery of cancer care in 
high-income countries (HICs) is the complex nature of 
multidisciplinary treatment and supportive services 
(coordinators, nurse specialists, patient navigators, 
pathology, and radiology) within cancer centres. These 
cancer centres have played an important part in 
the development of oncology in terms of refining 
existing treatments (eg, radiotherapy techniques, dosage, 
regimens, and equipment) and cancer surgery (eg, de-
escalating surgery in breast and rectal cancers for organ 
















Figure 1: Factors that can influence the development of a cancer centre
preservation, endoscopic treatment of early cancers, and 
surgical oncology techniques), as well as introducing new 
treatments and de-escalating existing ones (eg, avoiding 
fluorouracil in breast cancer adjuvant therapy, decreasing 
the number of cycles of therapy in breast and colon 
cancer, and refining e ndocrine t herapy)20,21 t hrough 
observational studies and clinical trials. These develop-
ments can be directly extrapolated to LMICs because the 
principles of cancer treatment are the same.22
Ongoing provision of high care standards is encouraged 
in HICs by adherence to the principles of clinical 
governance such as regular clinical audits, patient–public 
involvement, risk management, education and training 
of staff, adherence to evidence-based g uidelines, and 
robust management structures. Collaborations between 
cancer centres in HICs and those in LMICs have also 
played a key part in the development of translational and 
clinical research, including clinical trials.23
Education and training
In HICs, cancer centre development has been concurrent 
with the development of a professional cancer workforce. 
Cancer centres have a major role not only as foci for 
national training programmes but also in training 
pioneer cancer leaders from LMICs (eg, in childhood 
cancers24). Cancer centres in Japan have also had an 
important influence on the development of cancer 
centres in LMICs with a specific focus on surgery.25 
Additionally, health-care professionals from LMICs 
working in cancer centres in HICs have played a crucial 
part in the development of partnerships between LMICs 
and HICs in education and training.
Cancer centres as foci for developing workforce capacity 
and capability in high-income settings has been balanced 
by various national policies that encourage out-migration 
of workers to the private sector, or from rural to urban 
cancer centres, which leads to cancer centres in rural 
areas being understaffed. Solutions to this problem have 
been distinct and heterogeneous but some general lessons 
can be learned: first, c ancer c entres c an b e t he c entral 
focus for general cancer workforce training; second, 
national policies are needed to ensure that patients are 
referred and care is shared between cancer centres; and 
third, trainees need to be rotated proactively between 
different cancer centres.26
Strategic frameworks
Cancer centre development has been subject to the 
unique political economy and health system in each 
HIC. The formal template for the development and 
linkage of cancer centres has been led by the USA with 
its precise description and typologies of what makes a 
cancer centre comprehensive.27 However, this cancer 
centre model has not been replicable in other systems. 
The unique socioeconomics of cancer in the USA, 
coupled with the federal nature of care, its strong private 
sector, and high amount of research, creates both 
advantages and disadvantages for this national cancer 
centre model.28 However, the model has been highly 
effective for the development of cancer leadership 
globally, particularly to drive research. Crucial issues 
affecting comprehensive and non-comprehensive cancer 
centres in the USA are multiple and reflect the tensions 
and needs that can be found in most high-income 
settings. Affordability and equity of care are important 
issues for cancer centre sustainability in high-income 
settings, which drives improved networking.29 The rapid 
evolution of the research agenda is also creating an 
environment in which cancer centres are re-appraising 
their roles and deciding whether the era of population to 
laboratory research in a single cancer centre is feasible.30
Outside the USA, other countries such as France and 
the UK26 have sought to develop cancer centres within 
different strategic and legislative frameworks but with an 
increased emphasis on prevention, survivorship, patient 
experience, and quality of life after cancer. However, at 
their core, the research agenda has been similar to that 
driving cancer centres in the USA, with a substantial 
focus on translational cancer medicine and pharma-
ceutical cancer research. Analysis of research activities by 
site (eg, lung) or domain (eg, surgery) has shown a 
substantial deficit in the cancer research agenda that has 
been developed by cancer centres in HICs, particularly 
in radiotherapy, surgery, palliative care, and supportive 
care. The influence of political national leadership, 
philanthropic research funders, and the private sector 
has narrowed the research spectrum at the same time as 
many cancer centres are seeing unprecedented increases 
in research funding.
The global engagement of cancer centres in HICs in 
cancer centre development in LMICs has been modest. 
Although some centres have developed formal research 
and training engagement (eg, Academic Model Providing 
Access to Healthcare [AMPATH]31 and Partners in 
Health32), global cancer efforts has remained low on their 
development agenda. This situation partly reflects the 
priorities of research funders and national funding for 
care in HICs and partly a separation of agendas in terms 
of the development of expensive models of care. 
Despite these obstacles, cancer centres in HICs have 
developed some progressive and sustainable twinning 
models in adult and childhood cancers.23,33 The latter has 
been particularly successful with a combination of 
childhood cancer centre institutional support and specific 
research funders.34 Many of the global cancer program-
mes used in cancer centres in HICs have been built on 
substantial research and programme investments in 
infectious disease research (eg, in HIV/AIDS), which 
could offer opportunities for scaling up cancer centres in 
other settings.31,35
Overall, the development of cancer centres and models 
in HICs provides important lessons for cancer centre 
development in LMICs including, the delivery of quality 
optimal care that can be extrapolated to most settings, 
multidisciplinary working, and the use of local data to 
drive quality improvements. Importantly, each country 
should develop its own strategic approaches to cancer 
centre development that fit within their unique historical, 
social, and economic context.
Cancer centres in LMICs
Initiatives are being undertaken in LMICs to deliver 
optimal cancer care by developing cancer centres, but 
many of these initiatives are currently fragmented 
and uncoordinated. The challenges of quality, value, 
afford ability, and equality that cancer centres in HICs face 
are multiplied in LMICs. A further general challenge in 
cancer centre development is the restriction of funds to 
support public infrastructure development coupled with 
the challenges of trying to expand a suitable workforce. 
Additionally, limitations on research funding have meant 
that even cancer centres with major clinical and teaching 
portfolios often produce few research outputs. Even when 
research activity is substantial, it often mimics research 
that is done in cancer centres in HICs rather than 
reflecting the needs of local patients. In the past 10 years, 
LMICs have seen an explosion of private cancer centres 
that have been developed in a mostly unregulated 
manner.36 Deficits in public funding and the absence of a 
clear national vision and strategy, including failures to 
develop, fund, and deliver on health and cancer planning, 
have created a vacuum in public health care that has been 
rapidly filled by the private sector. Even in countries with 
traditionally strong public funding, such as Chile37 and 
Mexico,38 deficits in funding have caused public cancer 
centres to fall behind in terms of infrastructure invest-
ment. This situation has both driven and perpetu ated the 
move of patients, health-care professionals, and resources 
to private sector cancer centres. Furthermore, cancer 
centre development in LMICs is driven by a very different 
set of agendas, contexts, and political motivations leading 
to ad hoc, often irrational, expenditure on technologies 
(especially medicines) and projects with no effect on 
outcomes (eg, prostate-specific antigen screening in lieu 
of rational, phased development of cancer centre capacity 
and capability).
The different levels of cancer centres, which have 
usually been defined in high-income settings, are also 
subject to substantial heterogeneity in LMICs, as few 
countries have clear typologies, standards, and workloads 
within a formal accreditation system. LMICs have 
recognised the importance of a coherent strategy for 
developing cancer centres for national and global cancer 
control and are active in this area by building on pre-
existing internationally recognised cancer centres that 
deliver care, training, and research to international 
standards. Although emerging powers and low-income 
countries can be grouped together, the hugely hetero-
geneous nature of these countries, their health 
ecosystems, and historical contingencies should be 
recognised.
Asia
Asia has seen important developments in the expansion 
of cancer centres and access to care. The National Cancer 
Institute in Bangkok has a major influence on the 
development of cancer centres in Thailand and cancer 
units in several tertiary care hospitals, including 
university hospitals. Indonesia and the Philippines are 
still falling behind, with only a few cancer centres 
developed and long waiting lists for treatment, which is 
often compounded by their complex geography that 
includes thousands of islands. Bangladesh and Sri Lanka 
have made progress in the development of cancer 
centres.39 However, the pace of development has been 
dependent not just on national commitment to such 
projects, but also on geography—countries with 
numerous small island populations and other natural 
barriers experience serious challenges during the 
development of a cancer centre network.
In India, the development of cancer centres has been 
heavily influenced by sociodemographics; 70% of the 
population lives rurally but most cancer health-care 
professionals work in urban areas and nine out of ten of 
these professionals work in private sector cancer centres 
because of improved facilities and remuneration, and 
because of minimal accountability.40 Internationally 
recognised comprehensive cancer centres with substantial 
research portfolios can be found in major cities such as 
Delhi (All India Institute of Medical Sciences [AIIMS]), 
Mumbai (TMC), Kolkata (TMC), Chennai (Women’s 
Indian Association), Bengaluru (Kidwai Memorial), and 
Ahmedabad (Gujarat Cancer Research Institute). 
However, these centres face huge clinical volumes not 
seen in cancer centres in HICs (eg, 42 000 patients were 
treated by 188 staff in TMC Mumbai compared with 
41 000 patients treated by 1700 staff at MD Anderson 
Cancer Centre, University of Texas [Pramesh CS, 
unpublished]), leading to waiting times for diagnosis and 
treatment that can be in excess of 12 weeks. Despite this 
situation, public sector cancer centres have delivered 
research programmes relevant to the Indian population.41 
Additionally, 29 regional cancer centres have been 
established by the government of India under the National 
Cancer Control Programme (NCCP) since 1975.36
The uneven development of cancer centres in India is 
linked to an absence of leadership, funding, and 
commitment. Successes have included the unique model 
of TMC Rural Extension Project Nargis Dutt Memorial 
Cancer Hospital in Barshi, India, extending cancer 
treatment in rural and impoverished areas, which is a 
good example of coordination of a hub and spoke model 
in an LMIC, with TMC Mumbai acting as the hub (for 
complex care) and the cancer centre in Barshi being one 
of the spokes for cancer treatment.42 This project is a 
unique experiment in cancer centre development and 
has relevance for other transitioning countries to develop 
one major cancer centre as the hub that drives the 
development of other centres to deliver cancer care 
across the country. However, the BIMARU states of India 
(Bihar, Madhya Pradesh, Rajasthan, and Uttar Pradesh) 
have not seen successful cancer centre development 
possibly as a result of lower literacy rates, slower 
economic growth, and a higher corruption index than 
other regions of India.
Although efforts have been made to develop compre-
hensive cancer centres, unless there is governance on the 
quality of care with adherence to guidelines, these new 
cancer centres are not likely to improve patient outcomes. 
The Indian Council of Medical Research and the National 
Cancer Grid of India have made efforts t o publish 
guidelines and consensus statements for common 
cancers that can be used for quality improvement.17,43
Africa
In Africa, important strides have been made in cancer 
centre development in Algeria, Egypt, Ghana, Morocco, 
South Africa, Tanzania, and Tunisia. The National Cancer 
Institute in Cairo and the Moroccan cancer centre have 
been major catalysts for human resources in Africa. 
Morocco has 11 public sector cancer centres and is an 
exemplar of cancer centre development in Africa, 
especially in supporting human resource development in 
Francophone African countries such as Burkina Faso, 
Chad, Gabon, Mauritania, Niger, and Senegal.44 Tunisia 
provides cancer services through a comprehensive cancer 
centre in Tunis and cancer units in 24 university hospitals. 
However, Algeria, Egypt, Morocco, South Africa, and 
Tunisia account for 80% of all cancer centres and cancer 
treatment facilities in Africa. Large and populous African 
countries such as Democratic Republic of the Congo, 
Nigeria, and all Francophone African countries have 
substantially underdeveloped cancer centres. After the 
end of civil war in Angola in 2002, the government has 
invested in a modern cancer centre (National Oncology 
Centre) in Luanda, with all staff trained in Brazil, which 
was effective f or b uilding h uman r esources i nto c ancer 
centre development. However, sustaining these positive 
developments has proved extraordinarily challenging in 
the face of shifting political commitments and economic 
priorities.45
In Zambia, a major challenge for effective cancer 
control has been insufficient human resources in 
surgical oncology for urban cancer centres. To meet this 
need, the Zambia’s National Cancer Control Strategic 
Plan (2016–21) called for the development of in-country 
surgical oncology training in tertiary cancer centres. The 
focus of cancer centre development has been on building 
up the workforce capacity and capability for women’s 
cancers, facilitated by international collaborations with 
surgical oncologists from HICs.46 Once trained, surgical 
subspecialists are placed in rural cancer centres in which 
they offer standard surgical oncology services while 
serving as leaders for the development of these rural 
cancer centres. A major academic hospital, the University 
Teaching Women and Newborn Hospital, 
recently 
created a cancer centre by establishing a Gynaecologic 
Oncology Unit to improve the organisation and delivery 
of gynaecological cancer care. This development allowed 
the academic hospital and the newly created site-specific 
cancer centre to be approved as a site for the International 
Gynaecologic Cancer Society’s Global Training Program. 
Zambia has thus used the creation of cancer centres for 
a specific strategically driven focus around surgical 
oncology workforce. This focus is developed further with 
various research twinning grants such as the UK Medical 
Research Council grant to investigate the use of virtual 
surgical simulation-enhanced training and teleproctoring 
to enhance the transfer of surgical skills.
Like Zambia, Kenya has experimented with various 
public and private cancer centres over the past decade that 
have organically developed in response to need (Kenyan 
Network of Cancer Organisations).47 This experimentation 
has included novel models based on the dual strategy of 
twinning and building on existing clinical care 
infrastructure. AMPATH was initially coined for the 
Academic Model for the Prevention and Treatment of 
HIV/AIDS and was created in 2001, to address training 
issues in Kenya.31 The project started as an in-house 
training programme for health-care professionals to be 
trained in oncology to bridge a gap in the workforce in 
Kenya through international colla boration with cancer 
centres within the Moi University School of Medicine, the 
Moi Teaching and Referral Hospital, and a consortium of 
North American academic cancer centres led by Indiana 
University, USA.31 A key driver for this cancer centre 
development and international collaboration was the need 
to develop a programme for the management and care of 
around 50 000 previously screened women. Additionally, 
this cancer centre model was crucial for the expansion into 
wider oncology treatment. Around 8000 patients are now 
seen in medical and paediatric haematology and oncology 
clinics at AMPATH. Financial sustainability has been the 
major challenge, an issue seen in many LMIC cancer 
centres.48 For the AMPATH model in Kenya, philanthropic 
donations helped to meet costs, especially for drugs. 
Additionally, the Ministry of Health and the Kenyan 
Government have modified the National Hospital 
Insurance Fund to cover chemotherapy and radiotherapy. 
One issue has been the comprehen siveness of the medical 
insurance that covers Kenyan civil servants and their 
families, which is subsidised by taxpayers’ money, 
meaning that a proportionally greater amount of funding 
comes from people on lower incomes than those on higher 
incomes, making this approach hugely regressive. 
Philanthropy has allowed the Kenyian Chandaria Cancer 
and Chronic Care Centre to become a cancer centre, with 
capacity for around 10 000 patients as well as for cancer 
research and education.
Middle East
Cancer centre development in the Middle East has been 
greatly challenged by ongoing military and political 
conflicts. For many patients with cancer in Iraq and Syria, 
for example, the dismantling of previously robust health-
care infrastructure and cancer centres has led to regional 
patient travel in pursuit of reliable care.49 This movement 
has contributed to the rise of cancer centre hubs that aim 
to provide services, usually at a considerable cost, to 
migrants and local populations.50 As such, shortcomings 
in the provision of cancer care and cancer centres in the 
Middle East need to be understood as a regional rather 
than a national problem, with one of the fundamental 
barriers to coordinated cancer control being difficulties 
in financing care when state funding has been unsus-
tainable and unreliable. Numerous examples of individual 
pioneers such as the King Hussein Cancer Centre 
(KHCC), Cancer Institute of Iran, Tehran University of 
Medical Sciences, and the Kuwait Cancer Control Center, 
can be found in the development of cancer centres across 
the Middle East, such as in Iran and Kuwait, but the 
challenging and changing therapeutic geographies of 
these health systems impacted by long-term conflict 
shows how important context and history are in the 
realistic plan ning of cancer centre development. The 
trajectory taken by the KHCC in Jordan is one example of 
how cancer care is being transformed under the pressures 
of mass population movements across the region and the 
effects of war and conflict.
The KHCC, a non-governmental and non-profit institu-
tion, was founded in 1997 in response to the fragmentation 
of cancer care delivery nationwide.51 KHCC has developed 
into one of the region’s leading compre hensive cancer 
centres, treating around 60% of national cancer cases, and 
offering palliative and psychosocial care as part of the 
cancer care continuum.52 The success in scaling up cancer 
care services at KHCC have largely been attributed to 
strategic planning, which has included linkage of cancer 
care provision to medical training, residency programmes, 
emphasising improve ments in quality control, and sup-
port from external bodies.
Another element affecting cancer care provision at 
KHCC, and elsewhere in the region, is the rising number 
of medical travellers from countries of conflict such as 
Iraq, Sudan, Syria, and Yemen. The cost of cancer 
treatment has been kept low—a fraction of the cost in 
more recently developed health-care centres in Beirut—
and alternative non-profit insurance programmes funded 
by annual premiums allow comprehensive treatment of 
patients regardless of nationality. KHCC development 
also highlights the importance of external support for 
national strategies, which can add substantial value if 
used appropriately. The WHO made Jordan a demon-
strative project for palliative care52 and was the recipient of 
a transformational leadership title and support from the 
US National Cancer Institute.
The movement of populations in pursuit of health care 
across the region, particularly for cancer for which 
treatment is time-intensive and expensive, has local 
implications for national cancer care delivery. Across the 
Middle East, many health-care hubs are increasingly 
tailoring health-care services to medical travellers, 
providing assistance for paperwork and visa renewals, as 
well as accommodation. Many cancer centres in this 
region risk undermining access to cancer treatment at 
local levels because they focus on meeting regional 
demands. The effect of patient demographics, particularly 
on countries hosting refugees, should also not be 
underestimated. Cancer centre development in the region 
has been expected to rapidly increase capacity despite 
almost no international support.53
Latin America
The Brazilian National Cancer Institute and the 
Porto Alegre University Hospital have played a major 
part in developing cancer centres and generating vitally 
needed trained human resources for the Lusaphone 
African countries such as Angola, Guinea Bissau, and 
Mozambique. Since 2010, patients with cancer in Brazil 
have the right to be treated in a comprehensive cancer 
centre. Despite governmental efforts to certify new 
centres, only three out of 26 states have enough medium 
and high-level cancer centres (defined as one centre per 
500 000 people), including provision of radiotherapy. 
A national plan was created in 2012 to implement 80 new 
radiotherapy units. With this effort, nine of the states are 
expected to achieve adequate radiotherapy coverage for 
patients treated in the public sector.54
Brazil has 43 comprehensive cancer centres and 
249 cancer centres, most of which are in states in the 
south and on the east coast of the country. Patients in 
Brazil can travel huge distances to be treated at cancer 
centres, which can affect treatment compliance and cause 
delays in initiating treatment. According to a national law, 
all Brazilian citizens with cancer should receive their first 
treatment within 60 days of a pathology diagnosis of 
cancer, but this is challenging to deliver. An absence of 
centralisation into comprehensive cancer centres has led 
to workforce issues, especially in surgery. Despite breast 
reconstruction surgery being a civil right since 1999, up to 
60% of patients with breast cancer do not have access to 
reconstructive surgery as a result of a scarcity of trained 
reconstructive surgeons who are too spread out amongst 
the different cancer centres. However, despite this 
problem, breast  reconstruction has increased  from 15% 
in 2008 to 29% in 2014.55 Compounding challenges to 
cancer centre development in Brazil include the effect of 
the economic downturn in 2014, which has meant that 
since 2015 2 million Brazilians have lost their health 
benefit. According to a National Health Supplementary 
Agency policy published in 2016, this vacuum in public 
sector funding and in cancer centres will be fulfilled by 
the private sector, further driving inequalities and 
catastrophic expen ditures on cancer. Crucially, the scarcity 
of data on the mapping, volumes, and quality of cancer 
care in cancer centres is a major obstacle to creating 
evidenced-based policy.
The development of cancer centres in LMICs is crucial 
to the delivery of cancer care and improving outcomes 
for patients. However, LMICs have more heterogeneous 
and dynamic environments than HICs including in 
relation to workforce capacity, unregulated growth of the 
private sector, a scarcity of public sector investment in 
cancer centres, radically different migration patterns of 
patients, discontinuities in pathways of care, and a 
general absence of national strategies for cancer centre 
development, governance, sustainable financing, and 
accreditation (including tiering during which a centre 
provides some aspects of cancer care to a centre that 
provides comprehensive cancer care). Despite these 
challenges, many individual centres, countries, and 
networks have provided a rich mosaic of models and 
solutions for cancer centre development. National cancer 
centre strategies are needed to address inequality, 
including the public–private schism, distributional 
inequalities (geographical location of cancer centres to 
serve the greatest number of patients), and quality of 
care. Furthermore, although cancer centres are often 
perceived as centres of excellence in HICs, the converse 
is true in LMICs where they are perceived as places to 
die. Changing perceptions as well as the stage of cancer 
at which patients present with disease will be essential 
for cancer centre development in these radically different 
sociocultural settings.
Integration and distribution of cancer centres 
within health systems
Our analysis and exemplars of cancer centres described 
herein have discussed some of the challenges that cancer 
centre development in LMICs face. Policy makers have 
begun to address how to deliver equality in cancer care 
and national outcomes through a managed tiered 
approach to cancer centre development, including 
improved integration between individual cancer centres 
to deliver peer review, common guidelines, training, and 
research networks.56
Changes in health policy
Even in HICs, models of integration are evolving, 
constantly changing patterns of co-operation and 
competition in care, and finding new ways to build 
research networks between cancer centres. Changes to 
ideology and health policy in HICs have had substantial 
effects on cancer centre distribution and integration—
care close to home, competition, capacity building, and 
quality metrics have had both positive and negative effects 





























































Figure 2: Cancer centres in India that form part of the National Cancer Grid in 2017 compared with cancer centres in 1960
Image is courtesy of C S Pramesh.
complex, expensive technologies, especially in surgery 
and radiotherapy, also have a major effect on cancer centre 
distribution and organisation.57 The drive for improved 
value and outcomes is leading to changes in cancer centre 
integration and distribution on the basis of patient 
volumes, larger volume cancer centres, higher degrees of 
specialisation, and a greater drive to shared care models 
between the public and private sector. In HICs, the 
unintended consequences of policy and technology (eg, 
Da Vinci surgical system and cancer centres delivering 
prostate cancer care) also provide warnings to LMICs 
about how technopolitical currents can derail the best 
intentions around cancer centre strategies.57,58
New models of care
In many LMICs, patient migration in search of care has 
had a profound effect on cancer centre development. 
The location of 75 000 patients visiting the Tata Memorial 
Centre in Mumbai was mapped and showed that most 
patients travelled thousands of kilometres to get access to 
cancer treatment. This effect is also likely to be seen for 
other major comprehensive cancer centres in India, 
reflecting the scarcity of adequate cancer care facilities 
close to peoples’ homes.
Such migration has caused massive financial strain on 
public cancer centres and has led to an unregulated 
explosion of private cancer centres. In response, the 
National Cancer Grid of India has established a network 
of cancer centres across the country (figure 2) and has 
been a part of the development of new kinds of cancer 
centres to serve geographically isolated patient populations 
(eg, Assam in northeast India; panel 2; figure 3).
Outside country-specific initiatives to integrate cancer 
centres, notable models have been developed to bring 
together cancer centres with a site-specific and type-
specific focus—eg, breast cancer in Rwanda.59 With the 
considerable reduction of childhood communicable 
disease mortality over the past two decades in many 
LMICs, an expected increase in the incidence of 
childhood cancers (to that of HICs in the 1960s) has 
occurred.60 Many LMICs have created paediatric cancer 
centres to diagnose and treat children with cancer, often 
with the help of international twinning partners.33 Single-
hub cancer centres in LMICs see only 25–30% of the 
expected number of cases for each country, with Ghana 
being a notable example of a twinning partnership 
between Korle Bu Teaching Hospital, Accra and the Royal 
Hospital for Sick Children, Edinburgh, UK.61 This effect 
is due, in part, to the distances that patients have to travel 
to cancer centres, which are usually in capital cities. To 
overcome these challenges and optimise access for all 
children, efforts are being made to create networks of 
childhood cancer centres at the unit level with a hub or 
referral centre and shared care units spread across the 
country to match populated areas. Challenges have 
included recruitment of staff to rural cancer centres and 
the general issue of proper oversight and referral 
pathways because most cancer centres operate in an 
autonomous manner. For adults, cancer centres have 
been linked in LMICs through research, particularly 
clinical trial networks. However, most of these networks 
have been developed as a result of research funding from 
HICs and few networks in LMICs exist.62 The networks 
that do exist have managed to tie together both research 
and improved care as strategic drivers to bring cancer 
centres in different locations together. The Breast Health 
Global Initiative has brought together cancer centres to 
work on a resource stratification framework in which 
breast cancer manage ment strategies can be prioritised 
within the context of available health-care resources in 
fulfilment of the 2017 World Health Assembly Cancer 
Resolution to “adapt stepwise and resource-stratified 
guidance and tool kits” for compre hensive cancer 
prevention and control programs.63,64
Focus on quality of care
Initial cancer centre development in HICs and early 
adopters of cancer centres such as India show that high-
value care can be delivered by well-structured and 
organised national cancer centres that deliver 
geographical and socioeconomic equality. Achieving this 
goal requires political and clinical leadership with strong 
patient advocacy. Our analysis shows, however, that 
Panel 2: New cancer centre models in India
Tata Trusts in partnership with the Government of India, are rolling out a step-down 
distributed cancer centre model, commencing initially in north-east India. The vision is to 
create patient-centric cancer centres to deliver standardised and affordable care close to 
patients’ homes. The programme has six key factors:
Infrastructure development
The network will have three levels:
• Level 1: comprehensive cancer centres (around 200 beds) providing services ranging 
from diagnostics to complex therapies and research
• Level 2: cancer centres (around 100 beds) located near existing government medical 
colleges offering common diagnostic and treatment services with complex care being 
delivered at level 1
• Level 3: stand-alone day care cancer units near district hospitals offering diagnostics, 
chemotherapy, and radiotherapy
Awareness, prevention, and early detection
Health communication, prevention, and screening programmes for early detection
Community and hospital palliative care
Integration of clinical guidelines and training
Through the National Cancer Grid of India
Human resource development
Up-skilling and para-skilling the health-care workforce
Technology to link centres
Implementation of a Digital Nerve Centre to ensure seamless flow of patient information 
across centres. All the centres will be linked through teleradiology, telepathology, 
and virtual tumour boards
multiple pitfalls can occur that should be addressed. 
Many countries provide a wealth of models for cancer 
centres that have strengths and limitations; however, 
little structural funding exists to link different cancer 
centres together. Aligning political focus to support both 
national and international connections between 
institutions is essential considering the complexity of 
rapidly changing therapeutic geographies, and the fact 
that countries and regions are at very different stages of 
the cancer transition.65 Clinical leadership in cancer 
centres belong to heterogeneous coalitions with different 
degrees of power over national decision making and 
agenda setting. Developing networks of cancer centres 
requires an integrated approach to capacity and capability 
rather than a focus on surgical planning,66 radiotherapy 
infra structure,67 or generic discus sions around strength-
ening cancer systems. The popular strategy for cancer 
policy has been to treat these modalities and themes as 
special areas, yet the central aspect of the structures and 
organisation through which to deliver pathways and 
models of care in an equitable manner has been largely 
ignored. Pronounced challenges exist for co-ordinated 
multi disciplinary care and patient navigation within 
LMICs. To provide effective multi disciplinary treatment, 
focus should also shift towards data entry and 
maintenance of patient records. If medical records are 
disorganised or inaccessible, delivering coordinated care 
or doing research is not possible. Universal health 
coverage also provides the imprimatur for an analytical 
policy approach to public and private cancer centres, 
particularly for private cancer centres in which an 
absence of gover nance around structures, quality, 
outcomes, and geogra phical location has created huge 
systemic issues in many countries.68
Delivering cancer care in complex settings with 
competing health priorities
The social, economic, and political diversity both between 
and within countries has shaped the way in which cancer 
centres have developed. Challenges well beyond cancer, 
including the double and triple burden of disease in most 
LMICs, have shaped unique experiments in the structure 
and organisation of cancer centres. Likewise, the effect of 
the promotion of medical tourism through globalisation, 
and a focus on deregulation and privatisation, has 
damaged much needed progress on the public provision 
of cancer centres for many LMICs in the past two 
decades.69 However, despite the many challenges and 
setbacks that have been faced, a range of models and 
expertise are available internationally for the creation of 
cancer centres that promote the delivery of affordable, 
equitable, and high-quality care, as well as training and 
research within NCCPs. Crucially, cancer centres need 
clear public sector strategic direction and leadership that 
is built on local expertise but with an understanding of 
international context, by use of the best evidence base to 
create sound national policies for developing the 
 
infrastructure and human resources needed for that 
context.70 The reliance on ad-hoc review missions is 
insufficient for the long-term planning and commitment 
needed for a national network of public cancer centres. In 
this health policy analysis, a number of crucial issues and 
solutions emerge for global cancer centre development.
Health financing models
The paths for cancer towards Sustainable Development 
Goal 3 and universal health coverage will require, in 
addition to political commitment and technological 
innovation, substantial investment from governments 
and organisations.71 However, public monies alone are 
unlikely to be enough to achieve these targets. Innovative 
finance instruments and institutions are becoming 
increasingly relevant as alternative and sustainable 
sources of funding.72 The UK’s Department for 
International Development was the first bilateral 
institution to back an innovative model of mixed public 
and private funding—a development impact bond for 
education in Rajasthan, India. 3 years on, the education 
development impact bond is reporting promising results. 
How would a bond for cancer centre development work? 
Impact investors would provide start-up or growth capital 
for the setting up of a cancer centre and implementing 
organisations would use that capital to deliver cancer care 
services and possibly prevention services, depending on 
the structure of the investment and incentive, to a target 
population. The outcome funders (foundations, bilateral 
organisations, development banks, national governments, 
and insurance funds of emerging markets) would repay 
the investors their principal plus some extra amount if 
the targets are reached. Irrespective of the chosen 
instruments, transformative financing for cancer centres 
is needed to improve the standards of existing centres 

















Level 1 centres: comprehensive cancer centres
Level 2 centres: cancer centres
Level 3 centres: cancer units
Network of three comprehensive cancer centres, six cancer centres, and 11b cancer units will 
greatly improve patient access to cancer care, reducing travel time to less than 3 h
Figure 3: Developing and networking cancer centres in Assam, India
Image is courtesy of Arnie Purushotham.
Role of charities and patient advocacy groups
An unfortunate aspect of promoting cancer development 
in LMICs has been the absence of pressure from civil 
society for both the provision of universal health 
coverage and the push for increased biomedical 
research.74 In HICs, patients, families, and advocacy 
agencies have played a major part in stimulating cancer 
research and pushing for cancer treatments. Having 
said this, efforts have been made in LMICs to provide 
end of life care and palliation for patients with cancer 
and other diseases (eg, Hospice Uganda, CanSupport, 
India, and Pallium India, although more attention to 
this issue is needed).
Conclusion
Modern affordable and equitable cancer care and 
research demands the integration and fair distribution of 
cancer centres. However, our analysis of both HICs and 
LMICs shows that substantial challenges need to be 
addressed, including ensuring equitability between 
private and public cancer centres, distributional barriers 
due to extreme geography or lower development, the 
scarcity of trained health-care professionals, and 
distributional inequality due to the coalescing of cancer 
centres in the same, often urban, areas. Novel solutions 
do exist, but for these to be effective an alignment of 
political and cancer centre leader ship needs to occur, 
with incentives for co-operation and the removal of 
competitive market strategies.75 LMICs need to develop 
models for cancer centres that take into account the 
substantial mistakes made by HICs. Crucially, this 
development should be within the context of national 
planning for health systems, health human resources, 
and laboratory infrastructure, as well as rational and 
phased national cancer control planning underpinned by 
public total health-care expenditure.
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